Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Farmers Insurance
Deloitte
Healthtrust
AstraZeneca
Accenture
Argus Health
Boehringer Ingelheim
Baxter

Generated: November 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022369

« Back to Dashboard

NDA 022369 describes LATISSE, which is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the LATISSE profile page.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
Summary for 022369
Tradename:LATISSE
Applicant:Allergan
Ingredient:bimatoprost
Patents:11
Pharmacology for NDA: 022369
Ingredient-typeProstaglandins
Medical Subject Heading (MeSH) Categories for 022369
Suppliers and Packaging for NDA: 022369
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369 NDA Allergan, Inc. 0023-3616 0023-3616-03 1 BOTTLE, DROPPER in 1 CARTON (0023-3616-03) > 3 mL in 1 BOTTLE, DROPPER
LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369 NDA Allergan, Inc. 0023-3616 0023-3616-04 1 BOTTLE, DROPPER in 1 CARTON (0023-3616-04) > 3 mL in 1 BOTTLE, DROPPER

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;TOPICALStrength0.03%
Approval Date:Dec 24, 2008TE:ATRLD:Yes
Patent:➤ Sign UpPatent Expiration:Aug 25, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
Patent:➤ Sign UpPatent Expiration:May 25, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF INCREASING HAIR GROWTH
Patent:➤ Sign UpPatent Expiration:May 25, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF STIMULATING HAIR GROWTH

Expired US Patents for NDA 022369

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ➤ Sign Up ➤ Sign Up
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Merck
Julphar
US Department of Justice
Mallinckrodt
Fuji
Healthtrust
Farmers Insurance
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.